Valeant pledges to sweeten $47B bid for Allergan

Valeant Pharmaceuticals says it will sweeten the $46 billion it's offering along with Pershing Capital Management in an unsolicited bid for Allergan, after the Allergan board's rejection of the offer.

Pershing Capital Management, Valeant Pharmaceuticals, Allergan Inc.

News Well, Cosmetic/Aesthetic, Mergers & Acquisitions, Wall Street Beat

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1jXNgob